Computational modeling methods for qsar studies on HIV-1 integrase inhibitors (2005-2010)

Current Computer-Aided Drug Design

Volumn 8, Issue 4, 2012, Pages 255-270

  Ko, Gene M ^a   Srinivas Reddy, A ^b   Garg, Rajni ^a   Kumar, Sunil ^c   Hadaegh, Ahmad R ^d  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b LA JOLLA BIOENGINEERING INSTITUTE   (United States)

^c UTC Aerospace Systems   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

AIDS; Cheminformatics; Computational modeling; HIV 1 integrase inhibitors; HIV 1 integrase QSAR review; QSAR

Indexed keywords

BIOACTIVITY; COMPUTATION THEORY; COMPUTATIONAL CHEMISTRY; DISEASES; LEAST SQUARES APPROXIMATIONS; MOLECULAR GRAPHICS; VIRUSES;

AIDS; CHEMINFORMATICS; COMPUTATIONAL MODELLING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INTEGRASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INTEGRASE QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP REVIEW; INTEGRASE; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP;

MULTIPLE LINEAR REGRESSION;

AROMATIC AMIDE; BENZODITHIAZINE; BENZYL AMIDE KETOACID; CARBOXYLIC ACID DERIVATIVE; CICHORIC ACID; COUMARIN; CURCUMIN; CYCLOHEXANONE; DEPSIDE; DEPSIDONE; DIKETONE; FLAVONOID; HYDRAZIDE; INTEGRASE INHIBITOR; MERCAPTOBENZENE SULFONAMIDE; NAPHTHALENE; NAPHTHALIMIDE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; PHTHALIMIDE; QUINOLINONE 3 CARBOXAMIDE; RALTEGRAVIR; SALICYLHYDRAZINE; STYRYLQUINOLINE; SULFONAMIDE; SULFONE; TETRACYCLINE; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ALGORITHM; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER MODEL; DISCRIMINANT ANALYSIS; DRUG CONFORMATION; DRUG DESIGN; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84866869705     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/157340912803519624     Document Type: Article

References (109)

1. Barré-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vézinet- Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220, 868-871.
2. Broder, S.; Gallo, R.C. A pathogenic retrovirus (HTLV-III) linked to AIDS. N. Engl. J. Med., 1984, 311, 1292-1297.
3. Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go? J. Med. Chem., 2010, 53, 521-538.
4. Joint United Nations Programme on HIV/AIDS.UNAIDS Report on the Global AIDS Epidemic 2010; Geneva, Switzerland, 2010.
5. Mitsuya, H.; Weinhold, K.J.; Furman, P.A.; St Clair, M.H.; Lehrman, S.N.; Gallo, R.C.; Bolognesi, D.; Barry, D.W.; Broder, S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human Tlymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA, 1985, 82, 7096-7100.
6. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33, 307-320.
7. Shafer, R.W.; Schapiro, J.M. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev., 2008, 10, 67-84.
8. Carr, A.; Coopera, D.A. Adverse effects of antiretroviral therapy. Lancet, 2000, 356, 1423-1430.
9. Montessori, V.; Press, N.; Harris, M.; Akagi, L.; Montaner, J.S.G. Adverse effects of antiretroviral therapy for HIV infection. Can. Med. Assoc. J., 2004, 170, 229-238.
10. Mouscadet, J.F.; Delelis, O.; Marcelin, A.G.; Tchertanov, L. Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resist. Updat., 2010, 13, 139-150.
11. Maxfield, L.F.; Fraize, C.D.; Coffin, J.M. Relationship between retroviral DNA-integration-site selection and host cell transcription. Proc. Natl. Acad. Sci. USA, 2005, 102, 1436-1441.
12. McColl, D.J.; Chen, X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antiviral Res., 2010, 85, 101-118.
13. Malet, I.; Delelis, O.; Valantin, M.A.; Montes, B.; Soulie, C.; Wirden, M.; Tchertanov, L.; Peytavin, G.; Reynes, J.; Mouscadet, J.F.; Katlama, C.; Calvez, V.; Marcelin, A.G. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother., 2008, 52, 1351-1358.
14. Baldanti, F.; Paolucci, S.; Gulminetti, R.; Brandolini, M.; Barbarini, G.; Maserati, R. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J. Med. Virol., 2010, 82, 116-122.
15. Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature, 2010, 464, 232-236.
16. Garg, R.; Gupta, S.P.; Gao, H.; Babu, M.S.; Debnath, A.K.; Hansch, C. Comparative quantitative structure-activity relationship studies on anti-HIV drugs. Chem. Rev., 1999, 99, 3525-3602.
17. Kurup, A.; Mekapati, S.B.; Garg, R.; Hansch, C. HIV-1 protease inhibitors: A comparative QSAR analysis. Curr. Med. Chem., 2003, 10, 1679-1688.
18. Debnath, A.K. Application of 3D-QSAR techniques in anti-HIV-1 drug design - an overview. Curr. Pharm. Des., 2005, 11, 3091-3110.
19. Dudek, A.Z.; Arodz, T.; Galvez, G. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb. Chem. High Throughput Screen., 2006, 9, 213-228.
20. Cramer, R.D. III; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
21. Polanski, J.; Walczak, B. The comparative molecular surface analysis (COMSA): A novel tool for molecular design. Comput. Chem., 2000, 24, 615-625.
22. Hasegawa, K.; Matsuoka, S.; Arakawa, M.; Funatsu, K. Multi-way PLS modeling of structure-activity data by incorporating electrostatic and lipophilic potentials on molecular surface. Comput. Biol. Chem., 2003, 27, 381-386.
23. Klebe, G.; Abraham, U.; Meitzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37, 4130-4146.
24. Datar, P.A.; Khedkar, S.A.; Malde, A.K.; Coutinho, E.C. Comparative residue interaction analysis (CoRIA): A 3D-QSAR approach to explore the binding contributions of active site residues with ligands. J. Comput. Aided Mol. Des., 2006, 20, 343-360.
25. Waszkowycz, B.; Clark, D.E.; Frenkel, D.; Li, J.; Murray, C.W.; Robson, B.; Westhead, D.R. PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores. J. Med. Chem., 1994, 37, 3994-4002.
26. Hopfinger, A.J. A QSAR investigation of dihydrofolate reductase inhibition by Baker triazines based upon molecular shape analysis. J. Am. Chem. Soc., 1980, 102, 7196-7206.
27. Hopfinger, A.J.; Tokarski, J.S. In Practical Application of Computer-Aided Drug Design; Charifson, P. S., Ed.; Marcel Dekker: New York, 1997; pp. 105-163.
28. Hopfinger, A.J.; Wang, S.; Tokarski, J.S.; Jin, B.; Albuquerque, M.; Madhav, P.J.; Duraiswami, C. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc., 1997, 119, 10509-10524.
29. Duca, J.S.; Hopfinger, A.J. Estimation of molecular similarity based on 4D-QSAR analysis: Formalism and validation. J. Chem. Inf. Comput. Sci., 2001, 41, 1367-1387.
30. Duca, J.S.; Hopfinger, A.J. Estimation of molecular similarity based on 4D-QSAR analysis: formalism and validation. J. Chem. Inf. Comput. Sci., 2001, 41, 1367-1387.
31. Iyer, M.; Hopfinger, A.J. Treating chemical diversity in QSAR analysis: Modeling diverse HIV-1 integrase inhibitors using 4D fingerprints. J. Chem. Inf. Model., 2007, 47, 1945-1960.
32. Andrade, C.H.; Pasqualoto, K.F.M.; Ferreira, E.I.; Hopfinger, A.J. 4D-QSAR: perspectives in drug design. Molecules, 2010, 15, 3281-3894.
33. Bhhatarai, B.; Garg, R. From SAR to comparative QSAR: Role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2- ones HIV-1 protease inhibitors. Bioorg. Med. Chem., 2005, 13, 4078-4084.
34. Bhhatarai, B.; Garg, R. Comparative QSAR as a cheminformatics tool in the design of dihydro- pyranone based HIV-1 protease inhibitors. Curr. Comput.-Aided Drug Des., 2008, 4, 283-310.
35. Garg, R.; Bhhatarai, B. Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease. J. Comput. Aided Mol. Des., 2008, 22, 737-745.
36. Bhhatarai, B.; Garg, R.; Gramatica, P. Are mechanistic and statistical QSAR approaches really different? MLR studies on 158 cycloalkyl-pyranones. Mol. Inf., 2010, 29, 511-522.
37. Ko, G.M.; Reddy, A.S.; Kumar, S.; Bailey, B.A.; Garg, R. Computational analysis of HIV-1 protease protein binding pockets. J. Chem. Inf. Model., 2010, 50, 1759-1771.
38. Reddy, A.S.; Kumar, S.; Garg, R. Hybrid-genetic algorithm based descriptor optimization and QSAR models for predicting the biological activity of tipranavir analogs for HIV protease inhibition. J. Mol. Graph. Model., 2010, 28, 852-862.
39. Reddy, A.S.; Jalahalli, V.; Kumar, S.; Garg, R.; Zhang, X.; Sastry, G.N. Analysis of HIV protease binding pockets based on 3D shape and electrostatic potential descriptors. Chem. Biol. Drug Des., 2011, 77, 137-151.
40. Lameira, J.; Medeiros, I.G.; Reis, M.; Santos, A.S.; Alves, C.N. Structure-activity relationship study of flavone compounds with anti-HIV-1 integrase activity: A density functional theory study. Bioorg. Med. Chem., 2006, 14, 7105-7112.
41. Sahu, K.K.; Ravichandran, V.; Mourya, V.K.; Agrawal, R.K. QSAR analysis of caffeoyl naphthalene sulfonamide derivatives as HIV-1 integrase inhibitors. Med. Chem. Res., 2007, 15, 418-430.
42. Saíz-Urra, L.; González, M.P.; Fall, Y.; Gómez, G. Quantitative structure-activity relationship studies of HIV-1 integrase inhibition. 1. GETAWAY descriptors. Eur. J. Med. Chem., 2007, 42, 64-70.
43. Ravichandran, V.; Mourya, V.K.; Agrawal, R.K. QSAR analysis of 6-aryl-2, 4-dioxo-5-hexenoic acids as HIV-1 integrase inhibitors. Indian J. Pharm. Educ. Res., 2008, 42, 133-140.
44. Dessalew, N. Investigation of the structural requirement for inhibiting HIV integrase: QSAR study. Acta Pharm., 2009, 59, 31-43.
45. Cheng, Z.; Zhang, Y.; Fu, W. QSAR study of carboxylic acid derivatives as HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2010, 45, 3970-3980.
46. Li, B.J.; Chiang, C.C.; Hsu, L.Y. QSAR studies of 3,3'- (substituted-benzylidene)-bis-4-hydroxycoumarin, potential HIV-1 integrase inhibitor. J. Chin. Chem. Soc., 2010, 57, 742-749.
47. Ravichandran, V.; Shalini, S.; Sundram, K.; Sokkalingam, A.D. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2010, 45, 2791-2797.
48. Vengurlekar, S.; Sharma, R.; Trivedi, P. Two- and threedimensional QSAR studies on benzyl amide-ketoacid inhibitors of HIV integrase and their reduced analogues. Med. Chem. Res., 2010, 19, 1106-1120.
49. de Melo, E.B.; Ferreira, M.M.C. Multivariate QSAR study of 4,5- dihydroxypyrimidine carboxamides as HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2009, 44, 3577-3583.
50. Niedbala, H.; Polanski, J.; Gieleciak, R.; Musiol, R.; Tabak, D.; Podeszwa, B.; Bak, A.; Palka, A.; Mouscadet, J.F.; Gasteiger, J.; Le Bret, M. Comparative molecular surface analysis (CoMSA) for virtual combinatorial library screening of styrylquinoline HIV-1 blocking agents. Comb. Chem. High Throughput Screen., 2006, 9, 753-770.
51. Nunthaboot, N.; Tonmunphean, S.; Parasuk, V.; Wolschann, P.; Kokpol, S. Three-dimensional quantitative structure-activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA. Eur. J. Med. Chem., 2006, 41, 1359-1372.
52. Gupta, P.; Roy, N.; Garg, P. Docking-based 3D-QSAR study of HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2009, 44, 4276-4287.
53. Yuan, H.; Parrill, A. Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors. J. Mol. Graph. Model., 2005, 23, 317-328.
54. Leonard, J.T.; Roy, K. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2008, 43, 81-92.
55. Dhaked, D.K.; Verma, J.; Saran, A.; Coutinho, E.C. Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA). J. Mol. Model., 2009, 15, 233-245.
56. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model., 2002, 20, 269-276.
57. Tropsha, A.; Gramatica, P.; Gombar, V.K. The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci., 2003, 22, 69-77.
58. Barreca, M.L.; Ferro, S.; Rao, A.; De Luca, L.; Zappalà, M.; Monforte, A.M.; Debyser, Z.; Witvrouw, M.; Chimirri, A. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem., 2005, 48, 7084-7088.
59. Lu, P.; Wei, X.; Zhang, R. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV- 1 integrase. Eur. J. Med. Chem., 2010, 45, 3413-3419.
60. Fesen, M.R.; Kohn, K.W.; Leteurtre, F.; Pommier, Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. USA, 1993, 90, 2399-2403.
61. Mazumder, A.; Gazit, A.; Levitzki, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, Y. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry, 1995, 34, 15111-15122.
62. Zhao, H.; Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Milne, G.W.A.; Pommier, Y.; Burke, T.R., Jr. Coumarin-based inhibitors of HIV integrase. J. Med. Chem., 1997, 40, 242-249.
63. Nicklaus, M.C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G.W.A.; Pommier, Y. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching. J. Med. Chem., 1997, 40, 920-929.
64. Lin, Z.; Neamati, N.; Zhao, H.; Kiryu, Y.; Turpin, J.A.; Aberham, C.; Strebel, K.; Kohn, K.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; De Clercq, E.; Rice, W.G.; Pommier, Y.; Burke, T.R., Jr. Chicoric acid analogues as HIV-1 integrase inhibitors. J. Med. Chem., 1999, 42, 1401-1414.
65. Neamati, N.; Hong, H.; Sunder, S.; Milne, G.W.A.; Pommier, Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: Identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol., 1997, 52, 1041-1055.
66. Zhao, H.; Neamati, N.; Mazumder, A.; Sunder, S.; Pommier, Y.; Burke, T.R., Jr. Arylamide inhibitors of HIV-1 integrase. J. Med. Chem., 1997, 40, 1186-1194.
67. Neamati, N.; Turpin, J.A.; Winslow, H.E.; Christensen, J.L.; Williamson, K.; Orr, A.; Rice, W.G.; Pommier, Y.; Garofalo, A.; Brizzi, A.; Campiani, G.; Fiorini, I.; Nacci, V. Thiazolothiazepine inhibitors of HIV-1 integrase. J. Med. Chem., 1999, 42, 3334-3341.
68. Mazumder, A.; Neamati, N.; Sunder, S.; Schulz, J.; Pertz, H.; Eich, E.; Pommier, Y. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J. Med. Chem., 1997, 40, 3057-3063.
69. Neamati, N.; Hong, H.; Owen, J.M.; Sunder, S.; Winslow, H.E.; Christensen, J.L.; Zhao, H.; Burke, T.R., Jr.; Milne, G.W.A.; Pommier, Y. Salicylhydrazine-containing inhibitors of HIV-1 integrase: Implication for a selective chelation in the integrase active site. J. Med. Chem., 1998, 41, 3202-3209.
70. Zouhiri, F.; Mouscadet, J.F.; Mekouar, K.; Desmaële, D.; Savouré, D.; Leh, H.; Subra, F.; Le Bret, M.; Auclair, C.; d'Angelo, J. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J. Med. Chem., 2000, 43, 1533-1540.
71. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M.C.; Milne, G.W.A.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching. J. Med. Chem., 1997, 40, 942-951.
72. Xu, Y.W.; Zhao, G.S.; Shin, C.G.; Zang, H.C.; Lee, C.K.; Lee, Y.S. Caffeoyl naphthalenesulfonamide derivatives as HIV integrase inhibitors. Bioorg. Med. Chem., 2003, 11, 3589-3593.
73. Costi, R.; Di Santo, R.; Artico, M.; Roux, A.; Ragno, R.; Massa, S.; Tramontano, E.; La Colla, M.; Loddo, R.; Marongiu, M.E.; Pani, A.; La Colla, P. 6-Aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem. Lett., 2004, 14, 1745-1749.
74. Verschueren, W.G.; Dierynck, I.; Amssoms, K.I.E.; Hu, L.; Boonants, P.M.J.G.; Pille, G.M.E.; Daeyaert, F.F.D.; Hertogs, K.; Surleraux, D.L.N.G.; Wigerinck, P.B.T.P. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase. J. Med. Chem., 2005, 48, 1930-1940.
75. Petrocchi, A.; Koch, U.; Matassa, V.G.; Pacini, B.; Stillmock, K.A.; Summa, V. From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. Bioorg. Med. Chem. Lett., 2007, 17, 350-353.
76. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem., 2006, 49, 1506-1508.
77. Pasquini, S.; Mugnaini, C.; Tintori, C.; Botta, M.; Trejos, A.; Arvela, R.K.; Larhed, M.; Witvrouw, M.; Michiels, M.; Christ, F.; Debyser, Z.; Corelli, F. Investigations on the 4-quinolone-3- carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem., 2008, 51, 5125-5129.
78. Sato, M.; Kawakami, H.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Matsuzaki, T.; Yamataka, K.; Ikeda, S.; Shinkai, H. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem., 2009, 52, 4869-4882.
79. Sechi, M.; Rizzi, G.; Bacchi, A.; Carcelli, M.; Rogolino, D.; Pala, N.; Sanchez, T.W.; Taheri, L.; Dayam, R.; Neamati, N. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors. Bioorg. Med. Chem., 2009, 17, 2925-2935.
80. Chiang, C.C.; Mouscadet, J.F.; Tsai, H.J.; Liu, C.T.; Hsu, L.Y. Synthesis and HIV-1 integrase inhibition of novel bis- or tetracoumarin analogues. Chem. Pharm. Bull., 2007, 55, 1740-1743.
81. Johns, B.A.; Weatherhead, J.G.; Allen, S.H.; Thompson, J.B.; Garvey, E.P.; Foster, S.A.; Jeffrey, J.L.; Miller, W.H. 1,3,4- Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. Bioorg. Med. Chem. Lett., 2009, 19, 1807-1810.
82. Walker, M.A.; Johnson, T.; Naidu, B.N.; Banville, J.; Remillard, R.; Plamondon, S.; Martel, A.; Li, C.; Torri, A.; Samanta, H.; Lin, Z.; Dicker, I.; Krystal, M.; Meanwell, N.A. Benzyl amide-ketoacid inhibitors of HIV-integrase. Bioorg. Med. Chem. Lett., 2007, 17, 4886-4890.
83. Wai, J.S.; Egbertson, M.S.; Payne, L.S.; Fisher, T.E.; Embrey, M.W.; Tran, L.O.; Melamed, J.Y.; Langford, H.M.; Guare, J PJ.; Zhuang, L.; Grey, V.E.; Vacca, J.P.; Holloway, M.K.; Naylor- Olsen, A.M.; Hazuda, D.J.; Felock, P.J.; Wolfe, A.L.; Stillmock, K.A.; Schleif, W.A.; Gabryelski, L.J.; Young, S.D. 4-Aryl-2,4- dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem., 2000, 43, 4923-4926.
84. Grobler, J.A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A.S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J.S.; Young, S.; Vacca, J.; Hazuda, D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA, 2002, 99, 6661-6666.
85. Pais, G.C.G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E.S.; Pathak, V.K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T.R., Jr. Structure activity of 3-aryl-1,3- diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem., 2002, 45, 3184-3194.
86. Zhuang, L.; Wai, J.S.; Embrey, M.W.; Fisher, T.E.; Egbertson, M.S.; Payne, L.S.; Guare, J.P.; Vacca, J.P.; Hazuda, D.J.; Felock, P.J.; Wolfe, A.L.; Stillmock, K.A.; Witmer, M.V.; Moyer, G.; Schleif, W.A.; Gabryelski, L.J.; Leonard, Y.M.; Lynch, JJJ.; Michelson, S.R.; Young, S.D. Design and synthesis of 8-hydroxy- [1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem., 2003, 46, 453-456.
87. Hazuda, D.J.; Young, S.D.; Guare, J.P.; Anthony, N.J.; Gomez, R.P.; Wai, J.S.; Vacca, J.P.; Handt, L.; Motzel, S.L.; Klein, H.J.; Dornadula, G.; Danovich, R.M.; Witmer, M.V.; Wilson, K.A.A.; Tussey, L.; Schleif, W.A.; Gabryelski, L.S.; Jin, L.; Miller, M.D.; Casimiro, D.R.; Emini, E.A.; Shiver, J.W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science, 2004, 305, 528-532.
88. Johnson, A.A.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial. Curr. Top. Med. Chem., 2004, 4, 1059-1077.
89. Mao, P.C.M.; Mouscadet, J.F.; Leh, H.; Auclair, C.; Hsu, L.Y. Chemical modification of coumarin dimer and HIV-1 integrase inhibitory activity. Chem. Pharm. Bull., 2002, 50, 1634-1637.
90. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G.W.A.; Pommier, Y.; Burke, T.R., Jr. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem., 1997, 40, 937-941.
91. Maurer, K.; Tang, A.H.; Kenyon, G.L.; Leavitt, A.D. Carbonyl j derivatives: A new class of HIV-1 integrase inhibitors. Bioorg. Chem., 2000, 28, 140-155.
92. Bénard, C.; Zouhiri, F.; Normand-Bayle, M.; Danet, M.; Desmaële, D.; Leh, H.; Mouscadet, J.F.; Mbemba, G.; Thomas, C.M.; Bonnenfant, S.; Le Bret, M.; d'Angelo, J. Linker-modified quinoline derivatives targeting HIV-1 integrase: Synthesis and biological activity. Bioorg. Med. Chem., 2004, 14, 2473-2476.
93. Artico, M.; Di Santo, R.; Costi, R.; Novellino, E.; Greco, G.; Massa, S.; Tramontano, E.; Marongiu, M.E.; De Montis, A.; La Colla, P. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: Synthesis, biological evaluation, and molecular modeling. J. Med. Chem., 1998, 41, 3948-3960.
94. Costi, R.; Di Santo, R.; Artico, M.; Massa, S.; Ragno, R.; Loddo, R.; La Colla, M.; Tramontano, E.; La Colla, P.; Pani, A. 2,6- Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: Novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem., 2004, 12, 199-215.
95. Mekouar, K.; Mouscadet, J.F.; Desmaële, D.; Subra, F.; Leh, H.; Savouré, D.; Auclair, C.; d'Angelo, J. Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem., 1998, 41, 2846-2857.
96. Brzozowski, Z.; Saczewski, F.; Sanchez, T.; Kuo, C.L.; Gdaniec, M.; Neamati, N. Synthesis, antiviral, and anti-HIV-1 integrase activities of 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines. Bioorg. Med. Chem., 2004, 12, 3663-3672.
97. Brzozowski, Z.; S-awi-ski, J.; S-czewski, F.; Sanchez, T.; Neamati, N. Synthesis, anti-HIV-1 integrase, and cytotoxic activities of 4-chloro-N-(4-oxopyrimidin-2-yl)-2- mercaptobenzenesulfonamide derivatives. Eur. J. Med. Chem., 2008, 43, 1188-1198.
98. Meadows, D.C.; Mathews, T.B.; North, T.W.; Hadd, M.J.; Kuo, C.L.; Neamati, N.; Gervay-Hague, J. Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors. J. Med. Chem., 2005, 48, 4526-4534.
99. Sechi, M.; Derudas, M.; Dallocchio, R.; Dessì, A.; Bacchi, A.; Sannia, L.; Carta, F.; Palomba, M.; Ragab, O.; Chan, C.; Shoemaker, R.; Sei, S.; Dayam, R.; Neamati, N. Design and synthesis of novel indole _-diketo acid derivatives as HIV-1 integrase inhibitors. J. Med. Chem., 2004, 47, 5298-5310.
100. Dayam, R.; Sanchez, T.; Neamati, N. Discovery and structureactivity relationship studies of a unique class of HIV-1 integrase inhibitors. ChemMedChem, 2006, 1, 238-244.
101. Kuo, C.L.; Assefa, H.; Kamath, S.; Brzozowski, Z.; Slawinski, J.; Saczewski, F.; Buolamwini, J.K.; Neamati, N. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. J. Med. Chem., 2004, 47, 385-399.
102. Neamati, N.; Mazumder, A.; Zhao, H.; Sunder, S.; Burke, T.R., Jr.; Schultz, R.J.; Pommier, Y. Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother., 1997, 41, 385-393.
103. Ouali, M.; Laboulais, C.; Leh, H.; Gill, D.; Desmaële, D.; Mekouar, K.; Zouhiri, F.; d'Angelo, J.; Auclair, C.; Mouscadet, J.F.; Le Bret, M. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J. Med. Chem., 2000, 43, 1949-1957.
104. Deprez, E.; Barbe, S.; Kolaski, M.; Leh, H.; Zouhiri, F.; Auclair, C.; Brochon, J.C.; Le Bret, M.; Mouscadet, J.F. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol., 2004, 65, 85-98.
105. Burke, T.R., Jr.; Fesen, M.; Mazumder, A.; Yung, J.; Wang, J.; Carothers, A.M.; Grunberger, D.; Driscoll, J.; Pommier, Y.; Kohn, K. Hydroxylated aromatic inhibitors of HIV-1 integrase. J. Med. Chem., 1995, 38, 4171-4178.
106. Polishchuk, P.G.; Muratov, E.N.; Artemenko, A.G.; Kolumbin, O.G.; Muratov, N.N.; Kuz'min, V.E. Application of random forest approach to QSAR prediction of aquatic toxicity. J. Chem. Inf. Model., 2009, 49, 2481-2488.
107. Michielan, L.; Moro, S. Pharmaceutical perspectives of non-linear QSAR strategies.J. Chem. Inf. Model., 2010, 50, 961-978.
108. Svetnik, V.; Liaw, A.; Tong, C.; Culberson, J.C.; Sheridan, R.P.; Feuston, B.P. Random forest: A classification and regression tool for compound classification and QSAR modeling. J. Chem. Inf. Comput. Sci., 2003, 43, 1947-1958.
109. Bredel, M.; Jacoby, E. Chemogenomics: An emerging strategy for rapid target and drug discovery. Nat. Rev. Genet., 2004, 5, 262-275.